Lipid lowering with PCSK9 reduces the pro-inflammatory phenotype of monocytes

Schermafbeelding 2018-02-23 om 13.29.31

In the high impact European Heart Journal, The AMC group (Bernelot Moens et al) published a European Heart Journal paper on the impact of LDL cholesterol lowering on monocyte phenotype and function in patients with familial hypercholesterolaemia not using statins due to statin-associated muscle symptoms.. This open-access article can be found here (doi:10.1093/eurheartj/ehx002).

The group shows that lipid lowering with PCSK9 reduces the pro-inflammatory phenotype of monocytes without affecting C reactive protein, implying that potent lowering of LDL cholesterol has an anti-inflammatory impact in hypercholesterolemic patients. These data highlight that inflammation is not solely captured by C reactive protein mea

surement and warrant future investigations to assess the role of attenuating cellular inflammation in patients at high cardiovascular risk.

 

 

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N°667837.